Mankind Pharma announced an 11.5% increase in revenue for Q3 FY26, with an adjusted EBITDA margin of 25.9%. Domestic revenue increased by 11.1%. The company’s chronic share increased to 39.3%, driven by strong growth in cardiac and anti-diabetes segments. Revenue from OTC grew by 5.2%. BSV growth initiatives progressed well, showing strong double-digit growth. The company maintained its #1 rank with a prescription share of 15.2%.
Q3 FY26 Performance Highlights
Mankind Pharma reported the following key results for Q3 FY26:
- Revenue from Operations: INR 3,567 Crore, up by 11.5% YoY
- Domestic revenue: INR 3,046 Crore, up 11.1%
- Exports: INR 521 Crore, up 14.1% YoY
- Adjusted EBITDA margin: 25.9%
- PAT margin: 11.6%
Diluted EPS stood at INR 9.9, up by 6.7% YoY.
9M FY26 Performance Highlights
Key results for the nine months ended December 31, 2025 (9M FY26) include:
- Revenue from Operations: INR 10,835 Crore, up by 18.7% YoY
- Domestic revenue: INR 9,331 Crore, up 14.8%
- Exports: INR 1,504 Crore, up 50.8% YoY
- Adjusted EBITDA margin: 24.9%
- PAT margin: 12.7%
Diluted EPS was INR 32.9.
Domestic Business Performance
Domestic revenue registered a growth of 11.1% YoY, driven by growth in the base business and BSV consolidation. The company experienced strong performance in chronic growth with 16.7% growth in Cardiac and 14.4% in Anti-Diabetics. Glizid brand family crossed Rs 200 Cr in MAT December 2025 with 30%+ growth.
Consumer Healthcare Business
The Consumer Healthcare Business showed revenue growth of 5.2% YoY in Q3 FY26. MT & E-Com share increased to 13.1% in Q3 FY26. Gas-o-fast, Manforce Condom, and Ova news reported growth of 33%, 8%, and 36% YoY respectively.
Export Performance
Revenue growth for exports was 14% YoY, primarily driven by healthy growth in the BSV international business. Mankind excluding BSV has launched 4 new products in 9M FY26, taking the total launched products to 48 in the US.
Source: BSE
